Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris
- Conditions
- Interventions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-05-06
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 10
- Registration Number
- NCT00424801
- Locations
- 🇩🇰
Aarhus Hospital, Aarhus, Denmark
Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00416728
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00416468
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers
- Conditions
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 40
- Registration Number
- NCT00415883
- Locations
- 🇮🇳
Novartis Investigative Site, Mumbai, India
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
- Conditions
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1259
- Registration Number
- NCT00409643
- Locations
- 🇩🇪
Sites in Germany, Germany, Germany
🇺🇸Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00396656
- Locations
- 🇨🇭
Novartis Pharma Ag, Basel, Switzerland
Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome
- Conditions
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00394745
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
- Conditions
- Interventions
- Drug: CaptoprilDrug: EnalaprilDrug: LisinoprilDrug: RamiprilDrug: TrandolaprilDrug: BisoprololDrug: CarvedilolDrug: Metoprolol succinateDrug: CandesartanDrug: ValsartanDrug: EplerenoneDrug: SpironolactoneDrug: DiureticsDrug: HF treatment according to Swedish guidelinesProcedure: Blood samplesProcedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT00391846
- Locations
- 🇸🇪
Research Site, Vaxjo, Sweden
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
- Conditions
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 601
- Registration Number
- NCT00386607
- Locations
- 🇳🇱
Investigative Centers, Netherlands, Netherlands
GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2009-04-20
- Lead Sponsor
- Gruppo di Ricerca GISSI
- Target Recruit Count
- 1442
- Registration Number
- NCT00376272
- Locations
- 🇮🇹
CTO, Roma, RM, Italy
🇮🇹Ospedale Civile Saluzzo, Saluzzo, CN, Italy
🇮🇹Ospedale Civile G. Mazzini, Teramo, TE, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.